CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current Assets:
Cash and cash equivalents	$ 306,746,267	$ 43,393,570
Marketable securities	52,046,411	111,508,225
Accounts receivable, net of allowance for doubtful accounts of $1,941 at March 31, 2018 and $9,371 at June 30, 2017	195,046	488,723
Inventory		580,016
Prepaid expenses	4,276,134	891,284
Other current assets	5,894,556	436,344
Total current assets	369,158,414	157,298,162
Property and equipment, net of accumulated depreciation of $30,501,227 and $29,560,955 at March 31, 2018 and June 30, 2017, respectively	10,669,146	5,245,230
Other long-term assets	60,000	30,000
Total Assets	379,887,560	162,573,392
Current Liabilities:
Accounts payable and accrued expenses	23,196,457	31,366,976
Warrant liabilities	70,331,191	90,706,206
Deferred revenues	93,669	170,967
Total current liabilities	93,621,317	122,244,149
Convertible senior notes – net of unamortized debt issuance costs of $273,683 at March 31, 2018 and $1,915,781 at June 30, 2017	19,726,317	98,084,219
Non-recourse debt	182,216,000
Accrued interest expense on non-recourse debt	10,626,390
Other long-term liabilities	1,878,100	1,708,272
Total Liabilities	308,068,124	222,036,640
Commitments and Contingencies (Note 13)
Stockholders’ Equity (Deficit):
Common stock, $.01 par value; authorized 250,000,000 shares; issued 167,255,886 shares and outstanding 167,221,161 shares at March 31, 2018; issued 110,344,643 shares and outstanding 110,309,918 shares at June 30, 2017	1,672,558	1,103,446
Capital contributed in excess of par	750,391,976	462,666,366
Treasury stock, at cost: 34,725 shares at March 31, 2018 and at June 30, 2017	(458,370)	(458,370)
Accumulated deficit	(678,519,376)	(521,710,899)
Accumulated other comprehensive loss	(457,183)	(302,710)
Total Immunomedics, Inc. stockholders' equity (deficit)	72,629,605	(58,692,167)
Noncontrolling interest in subsidiary	(810,169)	(771,081)
Total stockholders’ equity (deficit)	71,819,436	(59,463,248)
Total Liabilities and Stockholders' Equity (Deficit)	379,887,560	162,573,392
Convertible preferred stock
Stockholders’ Equity (Deficit):
Convertible preferred stock, $.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at March 31, 2018 and 1,000,000 shares issued and outstanding at June 30, 2017		$ 10,000